Evidence map›Paper›PMID 38425644›Full record

ArticleFrontiers in pharmacology2024

Hyaluronic acid-ibuprofen conjugation: a novel ototherapeutic approach protecting inner ear cells from inflammation-mediated damage.

Bhaskar Birru, Joachim G S Veit, Elizabeth M Arrigali, Jack Van Tine, Emma Barrett-Catton, Zachary Tonnerre, Philippe Diaz, Monica A Serban

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Bhaskar Birru *Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Joachim G S Veit *Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Elizabeth M Arrigali *Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Jack Van TineDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Emma Barrett-CattonDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Zachary TonnerreDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Philippe DiazDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Monica A SerbanDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
University of Montana · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a substantial need of effective drugs for the treatment of hearing loss, which affects nearly 500 million individuals globally. Hearing loss can be the result of intense or prolonged noise exposure, ototoxic drugs, infections, and trauma, which trigger inflammatory signaling cascades that lead to irreversible damage to cochlear structures. To address this, we developed and characterized a series of covalent conjugates of anti-inflammatory drugs to hyaluronic acid (HA), for potential use as topical ototherapeutics. These conjugates were tested in

Indexed as

cochleahyaluronic acidibuprofeninflammationototherapeutic

Identifiers

PMID38425644
PMCPMC10902153
OpenAlexW4391841830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.